Sagar Lonial

Sagar Lonial, MD, FACP is Chief Medical Officer of Winship Cancer Institute, Professor and Chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine, and holds the Anne and Bernard Gray Family Chair in Cancer. He is one of the preeminent myeloma clinical investigators in the United States, recognized above all for his leadership in the DREAMM-2 trial — the pivotal phase II study of belantamab mafodotin (GSK2857916), an anti-BCMA antibody-drug conjugate, which demonstrated clinically meaningful single-agent activity in heavily pretreated patients refractory to proteasome inhibitors, IMiDs, and daratumumab, leading to FDA accelerated approval of belantamab mafodotin in 2020 as the first BCMA-targeted ADC. Beyond DREAMM-2, Dr. Lonial has been deeply involved in the clinical development of elotuzumab (anti-SLAMF7), contributing to the ELOQUENT-2 trial and helping define its role in myeloma combinations. His laboratory and clinical research span BCMA biology, myeloma cell signaling, the immunological basis of anti-myeloma therapy, and novel agent combinations. He has authored more than 400 peer-reviewed publications, serves on the Board of Directors of the American Society of Hematology, and is a frequent invited lecturer at major oncology meetings worldwide.